Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that
ranges from approximately 40% to 90% at 5 years following surgical management alone …

Opinion statement Patients with clinical stage III melanoma, defined as palpable lymph
nodes with or without in-transit metastases, have poor prognosis even with recent advances …

The global incidence of malignant melanoma, the leading cause of skin cancer death, has
steadily increased in recent years. Surgical excision is the treatment of choice for early-stage …

Simple Summary Patients with stage IIB-IV melanoma who have had surgery are
recommended to receive systemic adjuvant therapy, intended to target the residual micro …

Background With the development of novel systemic therapies, the treatment of patients with
melanoma has changed drastically over the past few years, especially with regard to …

Simple Summary The current standard of care for locally advanced melanoma is surgery first
followed by systemic therapy. However, there is growing evidence that neoadjuvant therapy …

The landscape of treatment options and outcomes for patients with locally advanced and
metastatic melanoma has changed dramatically in the past decade, with the introduction of …

Simple Summary Neo-adjuvant systemic (NAS) therapy for melanoma is leading the way in
immunotherapy for oncology. There is both a strong biological rationale to support NAS …

Simple Summary The risk of relapse for stage III melanoma remains high. Subsequently,
there has been a surge of interest in the role of contemporary therapies in the neoadjuvant …

Abstract Purposeof Review This review summarizes the current state of neoadjuvant
immunotherapy and targeted therapy for locoregionally advanced melanoma. Recent …